A Phase 1 Study of AJ1-11095 in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)

NCT06343805

Status	RECRUITING
Phase	Phase 1
Sponsor	Ajax Therapeutics, Inc.
Enrollment	76 participants

Key Eligibility Criteria

Inclusion (13)

- years of age or older.
- Diagnosis of PMF, post-PV MF, or post-ET MF.
- DIPSS Intermediate-2 or High-risk MF with d10% blasts, regardless of JAK2 mutation status.
- Estimated spleen volume e450cm3.
- MFSAF v.4.0 TSS e10, or at least 2 of 7 MFSAF-assessed symptoms with scores e3.

... and 8 more (see full listing online)

Exclusion (12)

- Prior splenectomy.
- Splenic irradiation within 3 months prior to first dose of study drug.
- Ongoing use of systemic corticosteroids at dose equivalent to \>10mg/day of prednisone.
- Uncontrolled intercurrent illness such as an acute infection.
- Chronic active or acute hepatitis B or C infection.

... and 7 more (see full listing online)

Locations (16 total)

Stanford Cancer Institute, Palo Alto, California, United States
Moffitt Cancer Cancer Center, Tampa, Florida, United States
University of Kansas Medical Center, Kansas City, Kansas, United States
... and 13 more locations

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at ClinicalTrials.gov. Generated by ClinicalTrialsFinder.org.